{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T06:44:18Z","timestamp":1768632258061,"version":"3.49.0"},"reference-count":31,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:00:00Z","timestamp":1768521600000},"content-version":"unspecified","delay-in-days":15,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Pfizer, Inc.","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["bmjpo"],"accepted":{"date-parts":[[2025,11,25]]},"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To estimate the incidence rates (IRs) of outcomes of interest in paediatric patients (aged 1 to &lt;2 years) treated with intravenous pantoprazole.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This real-world, non-interventional, retrospective study was conducted using Optum\u2019s longitudinal electronic health records database between 1 January 2007 and 31 December 2020. Eligible patients receiving \u22651 dose of intravenous pantoprazole were included. Premature patients and those with birth weight &lt;2.36 kg were excluded. Patients were divided into three subgroups based on diagnosis of gastro-oesophageal reflux disease (GORD) and erosive oesophagitis (EO): subgroup 1 (GORD and EO), subgroup 2 (GORD and no EO) and subgroup 3 (absence of both GORD and EO). The IRs (per 1000 person-years) of outcomes of interest were estimated in the overall and subgroups and stratified by duration of intravenous pantoprazole treatment (&lt;4 days vs \u22654 days).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 981 patients, none were identified in subgroup 1, while subgroup 2 and subgroup 3 comprised 462 (47.1%) and 519 (52.9%) patients, respectively. The highest IRs in the overall cohort were observed for vomiting (711.8), diarrhoea (412.4), abdominal distension (234.9), hypokalaemia (195.4) and hyponatraemia (182.5) with comparable IRs between subgroups 2 and 3. The IRs were higher for vomiting, diarrhoea, hypokalaemia, abdominal distension, hyponatraemia and thrombocytopenia in patients receiving \u22654\u2009days of pantoprazole treatment versus &lt;4\u2009days.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The real-world incidence of the outcomes of interest is consistent with the established safety profile of pantoprazole and may provide key insights for use of intravenous pantoprazole in paediatric patients excluding those born preterm or with low birth weight.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjpo-2025-003643","type":"journal-article","created":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T19:10:34Z","timestamp":1768590634000},"page":"e003643","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Safety of intravenous pantoprazole sodium in paediatric patients aged 1 year to &lt;2 years: a real-world retrospective cohort study in the USA"],"prefix":"10.1136","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6658-1213","authenticated-orcid":false,"given":"Sampada K","family":"Gandhi","sequence":"first","affiliation":[{"name":"Pfizer Inc, New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Taylor","sequence":"additional","affiliation":[{"name":"Aetion, Inc, New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lexie","family":"Rubens","sequence":"additional","affiliation":[{"name":"Aetion, Inc, New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nileesa","family":"Gautam","sequence":"additional","affiliation":[{"name":"Aetion, Inc, New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy A","family":"Sherman","sequence":"additional","affiliation":[{"name":"Pfizer Inc, New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Wolter","sequence":"additional","affiliation":[{"name":"Pfizer Inc, New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2026,1,16]]},"reference":[{"key":"2026011611102417000_10.1.e003643.1","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0000000000001889"},{"key":"2026011611102417000_10.1.e003643.2","doi-asserted-by":"publisher","DOI":"10.1177\/0091270010366146"},{"key":"2026011611102417000_10.1.e003643.3","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1097\/MPG.0000000000002280","article-title":"Prevalence of Gastroesophageal Reflux Disease Symptoms in Infants and Children: A Systematic Review","volume":"68","author":"Singendonk","year":"2019","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"2026011611102417000_10.1.e003643.4","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1177\/0890334416664711","article-title":"Association Between Infant Feeding Modes and Gastroesophageal Reflux: A Repeated Measurement Analysis of the Infant Feeding Practices Study II","volume":"33","author":"Chen","year":"2017","journal-title":"J Hum Lact"},{"key":"2026011611102417000_10.1.e003643.5","doi-asserted-by":"crossref","first-page":"263","DOI":"10.47102\/annals-acadmedsg.2021411","article-title":"Prevalence, risk factors and parental perceptions of gastroesophageal reflux disease in Asian infants in Singapore","volume":"51","author":"McLoughlin","year":"2022","journal-title":"Ann Acad Med Singap"},{"key":"2026011611102417000_10.1.e003643.6","article-title":"Proton Pump Inhibitors in Pediatric Gastroesophageal Reflux Disease: A Systematic Review of Randomized Controlled Trials","volume":"11","author":"Fern\u00e1ndez-Gonz\u00e1lez","year":"2024","journal-title":"Children (Basel)"},{"key":"2026011611102417000_10.1.e003643.7","first-page":"101","article-title":"Pantoprazole: an update of its pharmacological properties and therapeutic use in the management of acid-related disorders","volume":"63","author":"Cheer","year":"2003","journal-title":"Drugs (Abingdon Engl)"},{"key":"2026011611102417000_10.1.e003643.8","first-page":"11","article-title":"An update on the use of pantoprazole as a treatment for gastroesophageal reflux disease","volume":"3","author":"Mathews","year":"2010","journal-title":"Clin Exp Gastroenterol"},{"key":"2026011611102417000_10.1.e003643.9","unstructured":"PROTONIX (pantoprazole sodium) delayed-release tablets prescribing information. Available: https:\/\/labeling.pfizer.com\/showlabeling.aspx?id=135 [Accessed 20 Aug 2024]."},{"key":"2026011611102417000_10.1.e003643.10","unstructured":"PROTONIX I.V. (pantoprazole sodium)-prescribing information. Available: https:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=469 [Accessed 10 Sep 2024]."},{"key":"2026011611102417000_10.1.e003643.11","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0000000000001596"},{"key":"2026011611102417000_10.1.e003643.12","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1001\/jamapediatrics.2023.2900","article-title":"Proton Pump Inhibitor Use and Risk of Serious Infections in Young Children","volume":"177","author":"Lassalle","year":"2023","journal-title":"JAMA Pediatr"},{"key":"2026011611102417000_10.1.e003643.13","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDe2300280","article-title":"Trials and Tribulations - The Challenges of Clinical Trials in Children","volume":"2","author":"Furth","year":"2023","journal-title":"NEJM Evid"},{"key":"2026011611102417000_10.1.e003643.14","doi-asserted-by":"publisher","DOI":"10.1136\/archdischild-2019-318676"},{"key":"2026011611102417000_10.1.e003643.15","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)16942-0"},{"key":"2026011611102417000_10.1.e003643.16","unstructured":"PREA, PK and safety pass study of IV pantoprazole in pediatric subjects. Available: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/study\/NCT02401035 [Accessed 20 Aug 2024]."},{"key":"2026011611102417000_10.1.e003643.17","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1007\/s43441-023-00582-6","article-title":"Safety of Intravenous Pantoprazole Sodium in Pediatric Patients Aged 1 Month to\u2009<\u20091 Year: A Real-World Retrospective Cohort Study","volume":"58","author":"Gandhi","year":"2024","journal-title":"Ther Innov Regul Sci"},{"key":"2026011611102417000_10.1.e003643.18","unstructured":"Optum market clarity data. 2020. Available: https:\/\/business.optum.com\/en\/data-analytics\/life-sciences\/real-world-data\/market-clarity-data.html [Accessed 13 Oct 2025]."},{"key":"2026011611102417000_10.1.e003643.19","unstructured":"CDC . Growth charts\u2014data table of infant weight-for-age charts. Available: https:\/\/www.cdc.gov\/growthcharts\/cdc-charts.htm [Accessed 13 Oct 2025]."},{"key":"2026011611102417000_10.1.e003643.20","unstructured":"Rosner B . Fundamentals of Biostatistics. 7th edn. Boston: Cengage Learning. Inc, 2010."},{"key":"2026011611102417000_10.1.e003643.21","unstructured":"Aetion evidence platform. n.d. Available: https:\/\/aetion.com\/technology\/platform\/"},{"key":"2026011611102417000_10.1.e003643.22","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1097\/01.JAA.0000731488.99461.39","article-title":"Understanding gastroesophageal reflux disease in children","volume":"34","author":"Friedman","year":"2021","journal-title":"JAAPA"},{"key":"2026011611102417000_10.1.e003643.23","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-010-1321-3"},{"key":"2026011611102417000_10.1.e003643.24","doi-asserted-by":"crossref","first-page":"541","DOI":"10.2165\/11591900-000000000-00000","article-title":"Randomized, open-label, multicentre pharmacokinetic studies of two dose levels of pantoprazole granules in infants and children aged 1 month through <6 years with gastro-oesophageal reflux disease","volume":"50","author":"Tammara","year":"2011","journal-title":"Clin Pharmacokinet"},{"key":"2026011611102417000_10.1.e003643.25","doi-asserted-by":"publisher","DOI":"10.1177\/0091270010377501"},{"key":"2026011611102417000_10.1.e003643.26","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-39335-7"},{"key":"2026011611102417000_10.1.e003643.27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ajg.2022.10.012","article-title":"Pantoprazole associated dyspepsia hypocalcemia and hyponatremia: A disproportionality analysis in FDA adverse event reporting system (FAERS) database","volume":"24","author":"Nair","year":"2023","journal-title":"Arab J Gastroenterol"},{"key":"2026011611102417000_10.1.e003643.28","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ejim.2018.08.012","article-title":"Associations of proton pump inhibitors and hospitalization due to hyponatremia: A population-based case-control study","volume":"59","author":"Falhammar","year":"2019","journal-title":"Eur J Intern Med"},{"key":"2026011611102417000_10.1.e003643.29","first-page":"434","article-title":"Association of proton pump inhibitor use and significant hyponatremia-a US population-based case-control study","volume":"35","author":"El-Alali","year":"2022","journal-title":"Proc (Bayl Univ Med Cent)"},{"key":"2026011611102417000_10.1.e003643.30","doi-asserted-by":"publisher","DOI":"10.1007\/s00464-006-9136-1"},{"key":"2026011611102417000_10.1.e003643.31","unstructured":"AAP schedule of well-child care visits\u2014healthychildren.org. Available: https:\/\/www.healthychildren.org\/English\/family-life\/health-management\/Pages\/Well-Child-Care-A-Check-Up-for-Success.aspx [Accessed 19 May 2025]."}],"container-title":["BMJ Paediatrics Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjpo-2025-003643","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T19:10:46Z","timestamp":1768590646000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjpaedsopen.bmj.com\/lookup\/doi\/10.1136\/bmjpo-2025-003643"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1,16]]},"published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1136\/bmjpo-2025-003643"],"URL":"https:\/\/doi.org\/10.1136\/bmjpo-2025-003643","relation":{},"ISSN":["2399-9772"],"issn-type":[{"value":"2399-9772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]}}}